Key result
The overall prevalence of cardiovascular disease was 5%, with hypertension significantly increasing the odds of having CVD (aOR 2.68), while treatment uptake remained suboptimal at 22%.
Why the study?
Cardiovascular diseases cause nearly a third of deaths globally, prompting this study to understand the prevalence, prevention, and treatment of CVDs across twelve African countries.
Cross-Sectional (n=60,294)
Yes
Odds Ratio: 2.68 (95% CI 2.32–3.1)
p-value: p=<0.001
Despite a relatively low overall CVD prevalence of 5% in 12 African countries, the uptake of both preventive and therapeutic cardiovascular interventions remains critically suboptimal.
Highlights substantial gaps in CVD prevention and treatment across Africa; leaves open optimal strategies for improving care cascades in LMICs.
Introduction Cardiovascular diseases (CVDs) are responsible for nearly a third of deaths globally. We conducted this study to understand the prevalence of history of CVDs, their prevention and treatment in twelve African countries using the World Health Organization STEPwise Approach to Surveillance (WHO STEPS) data. Methods We used secondary STEPS data extracted from 12 African countries between 2014 and 2019. CVD was defined as a self-reported history of heart attack, angina, or stroke. Weighted percentages, counts, weighted odds ratios (OR), and the corresponding 95% confidence intervals (95%CI) were computed using the R software. We fitted logistic regression models to select the predictor variables from a regression model for CVD prevalence, CVD prevention and CVD treatment binary endpoints. Results Amongst 60,294 individuals, the prevalence of CVD was 5%. The CVD prevalence was higher in older individuals, females, individuals with hypertension, smokers, people with high salt intake, and in certain countries. Eleven percent of the 23,630 individuals at high risk of CVD (≥40 years) but without a history of the disease received CVD prevention treatment. Amongst the 2,895 persons with CVDs, 22% received treatment and counselling for CVD: 34% (n=215) receiving aspirin, 32% (n=202) counselling for CVD risk factors, 11% (n=66) statins, and 24% (n=148) both statins and aspirin. The uptake of CVD treatment varied by hypertension status, sex, age and country. Conclusion The prevalence of CVD was relatively low and CVD treatment uptake was sub-optimal. Concerted efforts must be made to accelerate the diagnosis and expand treatment for CVDs in Africa if to curtail untimely deaths attributable to CVDs.
No takes yet. Share an insight, caveat, or question.
Ng'ambi et al. (2025) conducted a cross-sectional in Cardiovascular diseases (CVD) (n=60,294). Hypertension vs. No hypertension was evaluated on Prevalence of cardiovascular disease (history of heart attack, angina, or stroke) (aOR 2.68, 95% CI 2.32-3.10, p=<0.001). The overall prevalence of cardiovascular disease was 5%, with hypertension significantly increasing the odds of having CVD (aOR 2.68), while treatment uptake remained suboptimal at 22%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: